The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 5-EU loses bid for speedier AstraZeneca vaccine deliveries

Fri, 18th Jun 2021 14:06

* Judge orders AstraZeneca to deliver doses by strict
deadlines

* EU had asked for more doses to be shipped earlier

* AstraZeneca may have breached contract in reserving doses
for UK

* Second legal case will establish whether contract was
breached
(Adds detail on timing of deliveries)

By Francesco Guarascio and Alistair Smout

BRUSSELS/LONDON, June 18 (Reuters) - The European Union on
Friday lost its bid to speed up deliveries of AstraZeneca's
COVID-19 vaccines, the first of its legal challenges against the
drugmaker that rocked the bloc as it scrambled to shore up
supplies.

AstraZeneca said the EU had lost its legal case, but
European Commission President Ursula von der Leyen said the
court ruling supported its view that the Anglo-Swedish
pharmaceutical giant had failed to honour its commitments.

The row plunged the EU into crisis earlier this year as
states, under pressure to speed up vaccinations, scrambled for
shots. Brussels has since largely cut ties with AstraZeneca,
choosing not to buy any more of its vaccines for now.

The drugmaker had committed to do its best to deliver 300
million doses to the 27-nation bloc by the end of June, but
production delays led it to revise this to 100 million vaccines.

This delayed the EU's vaccination drive as the bloc had
initially bet on AstraZeneca to deliver the largest volume,
sparking a bitter row and EU legal action to get at least 120
million doses by the end of June.

However, the judge ruled that AstraZeneca must deliver only
80.2 million doses by a deadline of Sept. 27. The drugmaker said
it would "substantially exceed" that by the end of June.

The court said in a statement that AstraZeneca must deliver
15 million doses by July 26, another 20 million by Aug. 23 and a
further 15 million by Sept. 27, to reach a total of 50 million
doses, which are in addition to 30 million that had been given
to the EU when the legal case began.

Should it miss the deadlines in the ruling, AstraZeneca
would face a penalty of "10 euros ($11.8) per dose not
delivered", the judge said, less than the 10 euros per dose per
day fine the EU had sought in bringing its legal action.

AstraZeneca will remain bound to do its best to deliver 300
million doses to the EU, and a new hearing is to be held in
September when compliance with the contract will be assessed
again, the ruling said.

The EU had asked all 300 million doses to be delivered by
the end of September, but the court did not set a deadline.

EU data shows the company has already shipped nearly 70
million doses, more than half of which were delivered after the
start of the legal proceedings.

This brings AstraZeneca close to already meeting the court's
requirement of 80 million doses in total by Sept. 27.

SERIOUS BREACH

An EU lawyer also said the judgment meant that as a proof of
best effort, AstraZeneca will have to deliver COVID-19 vaccines
from a factory in Britain, if needed to meet its EU commitments.

The company had said it could not immediately deliver to the
EU doses from an Oxford BioMedica factory because it had
to supply Britain first.

The ruling said that AstraZeneca may have committed a
serious breach of the contract by reserving Oxford BioMedica's
output for the British market. However a final decision on this
will be made in a second legal case.

AstraZeneca said the court had found that the EU had no
exclusivity or right of priority over other parties.

"The judgment also acknowledged that the difficulties
experienced by AstraZeneca in this unprecedented situation had a
substantial impact on the delay," it said in a statement.

"AstraZeneca now looks forward to renewed collaboration with
the European Commission to help combat the pandemic in Europe."

The EU last month launched a second legal action against
AstraZeneca over an alleged breach of the supply contract, which
will continue after the summer. Friday's ruling was over whether
AstraZeneca must speed up vaccine deliveries.
(Reporting by Francesco Guarascio in Brussels, Alistair Smout
in London, additional reporting by Muvija M in Bengaluru;
Editing by David Evans, Catherine Evans, Louise Heavens,
Alexander Smith and Barbara Lewis)

More News
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more
2 Jan 2024 08:48

LONDON MARKET OPEN: New Year begins largely green amid slew of PMIs

(Alliance News) - Stock prices in London opened mostly up on Tuesday, the first day of trading in 2024, reacting to slightly improved factory activity in China, with more manufacturing PMIs from major economies due.

Read more
2 Jan 2024 08:26

AstraZeneca and Sanofi received approval in China for RSV antibody

(Alliance News) - AstraZeneca PLC and Sanofi SA's long-acting monoclonal antibody Beyfortus received approval for use in China to prevent respiratory syncytial virus disease, Astra said on Tuesday.

Read more
2 Jan 2024 07:57

LONDON BRIEFING: AstraZeneca, Sanofi's RSV treatment approved in China

(Alliance News) - Stock prices in London are expected to open higher on Tuesday, reacting to a slight expansion in manufacturing activity in China and ahead of a slew of manufacturing PMI data including for the UK.

Read more
27 Dec 2023 17:04

Rate-cut optimism, autos push UK stocks higher

FTSE 100 up 0.4%, FTSE 250 adds 0.5%

*

Read more
27 Dec 2023 17:02

LONDON MARKET CLOSE: Stocks start week higher as 2024 draws to close

(Alliance News) - Equities in London kicked off an abbreviated trading week with gains on Wednesday, on continued US interest rate optimism at the end of 2024.

Read more
27 Dec 2023 14:25

London close: Stocks maintain gains amid post-Christmas rally

(Sharecast News) - London's stock markets closed in positive territory on Wednesday, buoyed by a global surge in stock prices as the S&P 500 neared an all-time high on Wall Street.

Read more
27 Dec 2023 12:06

LONDON MARKET MIDDAY: Stocks hold onto gains amid US rate cut hopes

(Alliance News) - London's FTSE 100 index was outperforming other European stock-price measures at midday on Wednesday, boosted by gains for miners and industrials.

Read more
27 Dec 2023 11:20

London midday: Stocks ride global wave of post-Christmas optimism

(Sharecast News) - London's equity markets were still above the waterline at lunchtime on Wednesday, following a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:48

LONDON MARKET OPEN: FTSE 100 gains led by miners and industrials

(Alliance News) - Stock prices in London opened in the green on Wednesday, as hopes for US interest rate cuts in the new year continued to propel global equities higher.

Read more
27 Dec 2023 08:26

London open: FTSE takes cues from Wall Street 'Santa rally'

(Sharecast News) - London's stocks returned from the Christmas break in the green on Wednesday, boosted by a late Santa rally on Wall Street overnight.

Read more
27 Dec 2023 08:24

TOP NEWS: AstraZeneca buys Gracell to "enrich" cell therapy pipeline

(Alliance News) - AstraZeneca PLC on Tuesday said it has agreed to acquire Gracell Biotechnologies Inc, paying about USD1.2 billion for the clinical-stage company.

Read more
27 Dec 2023 07:52

LONDON BRIEFING: AstraZeneca buys Gracell Biotech; COPL CEO resigns

(Alliance News) - Stocks in London were expected to make gains at Wednesday's market open, as investors continued to pin their hopes on US interest rate cuts.

Read more
27 Dec 2023 07:02

AstraZeneca to buy Gracell Technologies for $1.2bn

(Sharecast News) - AstraZeneca on Wednesday said it was buying Gracell Biotechnologies, a global clinical-stage biopharmaceutical company developing cell therapies for the treatment of cancer and autoimmune diseases, for $1.2bn.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.